Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation ...Middle East

SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization...

Hence then, the article about mirati therapeutics receives approval from the mhra for krazati adagrasib as a targeted treatment option for patients with advanced non small cell lung cancer nsclc with a krasg12c mutation was published today ( Saturday 04/11/2023 - 12:21 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation )

Also on site :

• Russian hockey legend Ovechkin refuses to wear LGBT tape
• After the Fire, Hope Valley Faces Its First Reckoning in 'When Calls the Heart' Season 13 Episode 3
• Simone Biles Stuns in Jonathan Owens-Inspired Outfit for NFL Playoff Game